Related Experiment Video
Updated: Jun 5, 2026
09:48
Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture
Published on: July 26, 2022
Protocol Optimization for Exosome Production From Umbilical Cord Mesenchymal Stem Cells: A Step Toward Clinical
Amir Bavafa1,2, Ali Sepehrinezhad1,2, Ali Gorji2,3,4
1Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Basic and Clinical Neuroscience
|June 4, 2026
Summary
This study presents a standardized protocol for isolating high-concentration exosomes from human umbilical cord mesenchymal stem cells (UC-MSCs). The method yields therapeutic-grade exosomes, crucial for advancing regenerative medicine and neurodegenerative disease treatments.
Area of Science:
- Biotechnology
- Regenerative Medicine
- Nanotechnology
Background:
- Exosomes, nano-scale extracellular vesicles, show promise for regenerative medicine and treating neurodegenerative diseases.
- Current isolation methods lack standardization, leading to inconsistencies and contamination risks, hindering clinical translation.
- Developing a reliable protocol is essential for harnessing exosome therapeutic potential.
Purpose of the Study:
- To introduce a standardized protocol for isolating high-concentration exosomes from human umbilical cord mesenchymal stem cells (UC-MSCs).
- To ensure the protocol adheres to Minimal Information for Studies of Extracellular Vesicles (MISEV) guidelines.
- To produce therapeutic-grade exosomes suitable for clinical applications.
Main Methods:
- UC-MSCs were cultured and conditioned in serum-free media.
- Exosomes were isolated using differential centrifugation, filtration, and dual ultracentrifugation.
- Characterization involved transmission electron microscopy (TEM), dynamic light scattering (DLS), bicinchoninic acid (BCA) assay, and western blotting for exosome markers (CD9, CD63) and a negative control (calnexin).
Main Results:
- TEM confirmed intact, spherical exosomes.
- DLS analysis indicated a monodisperse population with a size of 121.3±23.7 nm and stable zeta potential.
- High exosomal protein yield (1098.2 μg/mL) and confirmed presence of CD9/CD63 with absence of calnexin demonstrated purity and integrity.
Conclusions:
- The developed protocol yields standardized, reproducible, therapeutic-grade UC-MSC exosomes with high structural integrity and colloidal stability, meeting MISEV criteria.
- This method provides a foundation for translational studies in regenerative medicine and neurodegenerative disease treatment.
- Future research should focus on functional assays, cargo analysis, and scalability to further advance clinical applications.
